CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 545 enrolled
Drug / intervention
Tetanus-diphtheria-acellular pertussis (Tdap) vaccinebiological
Likely dose
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00347958
NCT00347958Phase 4Completed
CompareCT.gov

Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose

Sanofi Pasteur, a Sanofi Company·interventional·Posted Jul 4, 2006·Updated Dec 4, 2013

In Brief

A Phase 4 clinical trial evaluating Tetanus-diphtheria-acellular pertussis (Tdap) vaccine for Tetanus and 2 related conditions. Completed, enrolled 545 participants across 10 sites in 2 countries.

Detailed Summary

Objectives: To provide safety data on revaccination with ADACEL® vaccine. To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTetanus, Diphtheria, Pertussis
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2006
Enrollment StartAug 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.0 years ago

Interventions

Tetanus-diphtheria-acellular pertussis (Tdap) vaccinebiological

0.5mL, Intramuscular (IM)